Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node

 Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node

Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node

Shots:

  • The approval is based on P-III EORTC1325/KEYNOTE-054 trial results assessing Keytruda (pembrolizumab,200mg, q3w) vs PBO in 1019 patients in the ratio (1:1) with completely resected stage IIIA, IIIB or IIIC melanoma for 1yr or until disease recurrence or unacceptable toxicity
  • P-III EORTC1325/KEYNOTE-054 trial results: 43% reduction in the risk of disease recurrence or death; improvement in recurrence-free survival (RFS) benefit
  • Keytruda (pembrolizumab) 100mg IV is a mAb, used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2, further activating T lymphocytes

Click here to read full press release/ article| Ref: Merck | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post